|drug1691||Internet-based Cognitive Behavioral Therapy Wiki||0.71|
|drug2716||Quality of life promotion Wiki||0.71|
|D003141||Communicable Diseases NIH||0.05|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 2 clinical trials
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%. Furthermore, in our preliminary analysis, areas with existing BCG vaccination programs appear to have lower incidence and mortality from COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.
Description: The primary outcome measure is the development of COVID19 infection. We will use the Cox proportional-hazards model to calculate hazard ratios for the development of Covid-19. This will be reported as the proportion of individuals receiving the intervention who are PCR-positive or seroconvert. defined as number of new cases during the 6 month time periodMeasure: Incidence of COVID 19 Infection Time: 6 months
Description: The secondary outcome measure is disease severity calculated using the Covid Severity Scale Scoring of 0 -10. A score of 10 is worse and a score of 0 is best. Disease severity score will be based on the level of care required for individuals who test positive for COVID19 as follows: non-hospital-based care; patient hospitalized but no oxygen required; hospitalized and oxygen required; patient treated in intensive care and/or on mechanical ventilation; patient died. Additional WHO criteria for severity include severe pneumonia, respiratory failure, acute respiratory distress syndrome, sepsis and septic shock.Measure: Disease Severity Time: up to 6 months
The objective is to determine the safety and immunogenicity of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the safety and efficacy in prophylaxis of COVID-19.
Description: The number and proportion of subjects with adverse events observed until Day 43 post 1st vaccination are declared to be primary target variables.Measure: To assess the safety and tolerability of the COVID-19 vaccine Time: 43 days
Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s).Measure: Specific antibody response induced by the vaccine against the SARS-CoV-2 virus Time: 12 months
Description: Serum Neutralizing antibody levels.Measure: Neutralizing Antibodies Levels Time: 12 months
Description: Serum TNF-alpha levels.Measure: TNF-alpha Levels Time: 12 months
Description: Serum IFN-γ levels.Measure: Interferon Levels Time: 12 months
Description: Serum IL-2, -4, -5, -6 levels.Measure: Interleukine Levels Time: 12 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports